People often ask what is the evidence that alemtuzumab the most effective licensed DMT? It is all hidden in the data, in particular in relation to disability improvement and 'near normalisation' of brain volume loss. Alemtuzumab protects the end-organ; your brain. #ClinicSpeak pic.twitter.com/NldgJVI8Fn— Gavin Giovannoni (@GavinGiovannoni) September 30, 2018
Childhood obesity increases your risk of developing MS. Sugar is the main cause of childhood obesity. Does sugar cause MS and other autoimmune diseases? A virtually impossible question to address from a research perspective. #PreventMS https://t.co/rPdw460Xb7 pic.twitter.com/lnuxPVTmFh— Gavin Giovannoni (@GavinGiovannoni) September 30, 2018
It looks like this story is never going to go away. Please note that HBV vaccination is not associated with an increased risk of developing multiple sclerosis. #ClinicSpeak https://t.co/QIm84najss pic.twitter.com/bAmKYDEh14— Gavin Giovannoni (@GavinGiovannoni) September 30, 2018
UK MS Register stand at the Living with MS Torquay event. Thanks for having us. Looking forward to hearing many eminent speakers including @GavinGiovannoni, @KlausSchmierer and Djorje Gveric from the MS Tissue bank among others pic.twitter.com/btkzPP4U73— UKMSRegister (@UKMSRegister) September 29, 2018
My attempts to engage the wider MS community in Ireland & South Devon. My slides for download. #PreventMS #ThinkSocial #ClinicSpeak https://t.co/yinSr1keCh pic.twitter.com/2djeb4HPaZ— Gavin Giovannoni (@GavinGiovannoni) September 30, 2018
Accessing treatment as early as possible after the onset of #MultipleSclerosis symptoms could reduce the likelihood of requiring disability pension, according to a new large-scale study #MSresearch #MS https://t.co/0zGrgUjfwy
— Gavin Giovannoni (@GavinGiovannoni) September 30, 2018
Interesting paper exploring a sensitive cognitive-biomarker of memory dysfunction in MSers and its relationship to hippocampal volume. #TinkCognition and stop the shredder!! https://t.co/nwtzwWaXiR pic.twitter.com/ucsKYVW7Z0— Gavin Giovannoni (@GavinGiovannoni) September 29, 2018
Just arrived in Torquay for the South Devon MS Conference for MSers. Are you attending? #ClinicSpeak pic.twitter.com/X0CInXC57k— Gavin Giovannoni (@GavinGiovannoni) September 29, 2018
It looks like DMTs don't have any adverse psychiatric effects in MSers. If anything they help mood. #ClinicSpeak https://t.co/IvNUBc7J7a pic.twitter.com/PUtRssY5Hn— Gavin Giovannoni (@GavinGiovannoni) September 27, 2018
Guest Post: The Real, Real Deal with Exercising and MS, by Dave Bexfield #GuestPost #ClinicSpeak https://t.co/ut9la3eHuh pic.twitter.com/3kzuiiN3P9— Gavin Giovannoni (@GavinGiovannoni) September 27, 2018
I wonder if the therapeutic nihilists are eating their hats? #ClinicSpeak The long-term effectiveness of interferon-beta and glatiramer acetate in MS: 10-year results from the UK's Risk-Sharing Scheme https://t.co/QqYZ21KdBn pic.twitter.com/WsYJD7FJll— Gavin Giovannoni (@GavinGiovannoni) September 26, 2018
Another example of variation in the access to treatments for MSers living in the UK. #ClinicSpeak There are no standard procedures for assessing and providing assistive devices for MSers in United Kingdom? Good thing we are holding a meeting on this issue. https://t.co/wS5cIEbHMi pic.twitter.com/fcCvtkcgZK— Gavin Giovannoni (@GavinGiovannoni) September 26, 2018
Great to see an emerging evidence-base emerging for using exercise as a treatment for MS. #ClinicSpeak Home-based, square-stepping exercise program among older adults with multiple sclerosis: results of a feasibility randomized controlled study. https://t.co/NQ05N2hfug pic.twitter.com/1sXlIhffQg— Gavin Giovannoni (@GavinGiovannoni) September 26, 2018
Yet another device to objectively measure the damage caused by MS. By the time we have used the plethora of emerging devices on each MSer they will be deviced-out ;-) #ClinicSpeak Validation of a Precision Tremor Measurement System for Multiple Sclerosis. https://t.co/VDqPDWLbVg pic.twitter.com/z3MbkLcS0t— Gavin Giovannoni (@GavinGiovannoni) September 26, 2018
Clearly medical decision-making is more complex than I thought. #ClinicSpeak Probability discounting of treatment decisions in MS: associations with disease knowledge, neuropsychiatric status, and adherence. https://t.co/tl0dbBaSNy pic.twitter.com/vzwhJkOLXt— Gavin Giovannoni (@GavinGiovannoni) September 25, 2018
This study shows why brain volume measures are unlikely to become part of routine clinical care in MS.; simply too many factors to consider. #ClinicSpeak Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements .. https://t.co/rPvFuNTSyT pic.twitter.com/vQR28GjiwE— Gavin Giovannoni (@GavinGiovannoni) September 25, 2018
Positive news, at least for Danish mothers with MS; your children's' mental health will be fine. #ClinicSpeak This Danish study did not confirm other reports that the mental health of children of mothers with MS is compromised. https://t.co/8XuKJHi3dm pic.twitter.com/P83WaMicHs— Gavin Giovannoni (@GavinGiovannoni) September 25, 2018
Ginger, ginger everywhere but no clinical evidence to support its therapeutic use. #ClinicSpeak This sort of review encourages premature adoption of dietary interventions in MS. This is really only a hypothesis paper and a call for more research. https://t.co/lDKqJSpC80 pic.twitter.com/fRMDuDp4sT— Gavin Giovannoni (@GavinGiovannoni) September 24, 2018
A wonderful idea to get more disabled MSers cycling. However, the NHS is unlikely to have the resources to implement this. #ClinicSpeak A pilot trial of functional electrical stimulation (FES) cycling exercise in MSers with mobility disability. https://t.co/nsJPp6s0nd pic.twitter.com/b4lKepqcQK— Gavin Giovannoni (@GavinGiovannoni) September 24, 2018
As promised my slides from last week's MS Ireland meeting in Athlone. You can download the presentations and ask me questions on the presentations. https://t.co/y3cj4PUuiP pic.twitter.com/JIfZUqI8uw— Gavin Giovannoni (@GavinGiovannoni) September 24, 2018
What’s exciting about the future of #MS treatment? Grace from shiftms interviews Jodi Haartsen, #MS nurse practitioner https://t.co/zHG9rNs8fl #MultipleSclerosis— Gavin Giovannoni (@GavinGiovannoni) September 24, 2018
Another study fingering memory B-cells as the common target of DMTs. #ResearchSpeak B-cell composition in the blood and cerebrospinal fluid of MSers treated with dimethyl fumarate. #ClinicSpeak https://t.co/AhVaElsBeL pic.twitter.com/cppSrfzo21— Gavin Giovannoni (@GavinGiovannoni) September 24, 2018
An interesting use of Bayesian statistics to create a risk estimate at disease onset (BREMSO) to predict outcome. It will need validation but it correlated with cognitive and physical disability in MSers with early disease. #ResearchSpeak https://t.co/F39TlmGkyB pic.twitter.com/jVJF1vsOAu— Gavin Giovannoni (@GavinGiovannoni) September 24, 2018